rwdd3 Antibody

What is RWDD3 and why is it a target of interest for cancer research?

RWDD3 (RSUME) is a small RWD-containing protein that functions as an enhancer of SUMO conjugation in the regulatory network of immune-inflammatory signals. It interacts with UBE2I/UBC9 and raises SUMO conjugation to proteins by promoting the binding of E1 and E2 enzymes, as well as the transfer of SUMO to specific target proteins including HIF1A, PIAS, NFKBIA, NR3C1, and TOP1 . RWDD3 has been implicated in pituitary tumors and significantly upregulated in glioblastoma tissues compared to normal brain tissues . Studies have demonstrated that RWDD3 knockdown inhibits glioblastoma cell proliferation, induces cell cycle arrest, promotes apoptosis, and reduces invasion and migration capabilities, making it a promising target for glioblastoma research and potential therapeutic interventions .

Which tissues show significant RWDD3 expression that would be suitable for positive controls?

RWDD3 is expressed across a wide range of tissues, with notably high expression in cerebellum, pituitary, heart, kidney, liver, stomach, pancreas, prostate, and spleen . When validating RWDD3 antibodies, these tissues would serve as appropriate positive controls. Additionally, glioma tumor samples express both isoform 1 and isoform 2 at the protein level . For negative or low expression controls, tissues with documented low RWDD3 expression include thalamus and spinal cord . For cell line-based positive controls, glioblastoma cell lines such as U87 and U251 express significantly higher levels of RWDD3 compared to normal human astrocytes and would be suitable as positive control samples for antibody validation .

What are the key differences between the isoforms of RWDD3 that researchers should consider when selecting antibodies?

RWDD3 has multiple isoforms, with isoform 1 and isoform 2 being the most studied. Both isoforms positively regulate the NF-kappa-B signaling pathway by enhancing the sumoylation of NF-kappa-B inhibitor alpha (NFKBIA), which promotes its stabilization and consequently leads to increased inhibition of NF-kappa-B transcriptional activity . Similarly, both isoforms negatively modulate the hypoxia-inducible factor-1 alpha (HIF1A) signaling pathway by increasing HIF1A sumoylation, affecting its insertion, transcriptional activity, and expression of target genes like VEGFA during hypoxia .

When selecting antibodies, researchers should determine whether their experimental questions require isoform-specific detection or general RWDD3 detection. Antibodies raised against amino-terminal epitopes may differentiate between isoforms if they have distinct N-termini, as suggested by some commercially available antibodies being raised against "a 17 amino acid synthetic peptide from near the amino terminus of human RWDD3" . For comprehensive detection of all RWDD3 isoforms, antibodies targeting conserved regions would be more appropriate.

How does RWDD3 regulate the PI3K/AKT signaling pathway in glioblastoma, and how can antibodies help elucidate this mechanism?

RWDD3 appears to play a crucial role in modulating the PI3K/AKT signaling pathway in glioblastoma cells. Research has demonstrated that knockdown of RWDD3 significantly downregulates the phosphorylation levels of PI3K and AKT in glioblastoma cell lines U87 and U251 . The PI3K/AKT pathway is crucial for survival, proliferation, and motility of multiple cell types, and its dysregulation is implicated in various cancer types including glioblastoma .

To elucidate this mechanism, researchers can use RWDD3 antibodies in multiple applications:

• Co-immunoprecipitation studies: To identify direct protein-protein interactions between RWDD3 and components of the PI3K/AKT pathway.

• Phospho-specific antibody assays: Following RWDD3 knockdown or overexpression, researchers can use antibodies against phosphorylated PI3K and AKT to monitor pathway activation.

• Chromatin immunoprecipitation (ChIP): To determine if RWDD3 associates with promoter regions of genes involved in the PI3K/AKT pathway.

• Immunofluorescence studies: To visualize subcellular localization changes of RWDD3 and PI3K/AKT components under different cellular conditions.

Interestingly, when the PI3K/AKT pathway is activated using an agonist like 740Y-P following RWDD3 knockdown, the suppressive effects on glioblastoma cell proliferation and migration are rescued, confirming that RWDD3 exerts its oncogenic effects at least partly through the PI3K/AKT signaling pathway .

What is the role of RWDD3 in modulating SUMO conjugation, and how can this be studied using antibodies?

RWDD3 functions as an enhancer of SUMO conjugation through its interaction with UBE2I/UBC9 . It promotes the binding of E1 and E2 enzymes, facilitates thioester linkage between SUMO and UBE2I/UBC9, and enhances the transfer of SUMO to specific target proteins including HIF1A, PIAS, NFKBIA, NR3C1, and TOP1 .

To study RWDD3's role in sumoylation, researchers can employ several antibody-based approaches:

• Sequential immunoprecipitation: First immunoprecipitating with anti-SUMO antibodies, then probing with anti-RWDD3 or vice versa to detect SUMO-RWDD3 complexes.

• In vitro sumoylation assays: Using recombinant proteins and RWDD3 antibodies to study how RWDD3 affects the efficiency of SUMO conjugation to target proteins.

• Proximity ligation assays (PLA): To visualize direct interactions between RWDD3 and components of the sumoylation machinery in situ.

• Western blot analysis: Following RWDD3 modulation, researchers can use antibodies against sumoylated proteins to assess changes in global sumoylation patterns or specific targets.

This mechanistic understanding is important as RWDD3-enhanced sumoylation of IκB leads to inhibition of NF-κB activity on inflammatory genes like IL-8 and cyclooxygenase-2 (Cox-2), potentially favoring anti-inflammatory pathways .

How do hypoxic conditions affect RWDD3 expression and function, and what experimental approaches can detect these changes?

RWDD3 expression is induced under hypoxic conditions, suggesting a potential role during vascularization . This hypoxia-induced expression may be particularly relevant in tumor microenvironments where hypoxia is common. Furthermore, RWDD3 has been shown to negatively modulate the hypoxia-inducible factor-1 alpha (HIF1A) signaling pathway by increasing HIF1A sumoylation, which affects its insertion, transcriptional activity, and the expression of its target gene VEGFA during hypoxia .

To study RWDD3 changes under hypoxic conditions, researchers can use:

• Quantitative immunoblotting: Using RWDD3 antibodies to measure protein expression changes in normoxic versus hypoxic conditions.

• Immunofluorescence microscopy: To visualize changes in subcellular localization of RWDD3 during hypoxia.

• ChIP-qPCR: To assess whether hypoxia affects RWDD3 binding to specific genomic regions.

• Co-immunoprecipitation: To determine if hypoxia alters RWDD3's interaction with HIF1A or other hypoxia-responsive proteins.

• SUMO-IP followed by RWDD3 detection: To examine whether hypoxia changes the proportion of sumoylated RWDD3.

These approaches can help elucidate the bidirectional relationship between RWDD3 and hypoxia signaling, which may be particularly relevant in understanding tumor vascularization mechanisms.

What are the optimal conditions for using RWDD3 antibodies in immunohistochemistry of brain tumor samples?

When performing immunohistochemistry (IHC) to detect RWDD3 in brain tumor samples, particularly glioblastoma, researchers should consider the following optimization steps:

• Tissue fixation and processing: Formalin-fixed paraffin-embedded (FFPE) tissues typically require antigen retrieval. For RWDD3, heat-induced epitope retrieval in citrate buffer (pH 6.0) is often effective, but this should be optimized as epitope accessibility can vary between antibodies.

• Antibody dilution: Commercial RWDD3 antibodies such as polyclonal rabbit antibodies should be tested in a dilution series (typically starting at 1:100-1:500) to determine optimal signal-to-noise ratio .

• Incubation conditions: Primary antibody incubation is typically performed overnight at 4°C to maximize specific binding while minimizing background.

• Detection system: Given that RWDD3 may have variable expression levels across different regions of glioblastoma tissues, a sensitive detection system such as polymer-based or amplification methods may be necessary.

• Controls: Include positive controls (tissues known to express RWDD3 such as cerebellum, pituitary, or confirmed glioblastoma samples) and negative controls (primary antibody omission and tissues with low RWDD3 expression like thalamus) .

• Counterstaining: Hematoxylin counterstaining can help visualize tissue architecture and cellular context of RWDD3 expression.

For validation, parallel staining with multiple antibodies targeting different epitopes of RWDD3 can confirm specificity, and correlation with RWDD3 mRNA expression data from the same samples can further validate IHC results.

What is the most effective protocol for using RWDD3 antibodies in cell-based assays to study its role in glioblastoma?

For studying RWDD3's role in glioblastoma using cell-based assays, researchers should consider multiple approaches:

• Immunofluorescence microscopy:

  • Fix cells using 4% paraformaldehyde (15 minutes at room temperature)

  • Permeabilize with 0.1% Triton X-100 (10 minutes)

  • Block with 5% BSA (1 hour)

  • Incubate with primary RWDD3 antibody (1:200-1:500 dilution, overnight at 4°C)

  • Wash and incubate with fluorescent secondary antibody (1:1000, 1 hour at room temperature)

  • Counterstain nuclei with DAPI

  • This approach allows visualization of subcellular localization and co-localization with other proteins of interest

• Flow cytometry:

  • For intracellular RWDD3 detection, fix and permeabilize cells

  • Incubate with RWDD3 antibody followed by fluorescently-labeled secondary antibody

  • This method enables quantitative assessment of RWDD3 expression levels across cell populations and can be combined with cell cycle analysis

• Western blotting:

  • Lyse cells in RIPA buffer supplemented with protease and phosphatase inhibitors

  • Separate 30-50 μg of protein by SDS-PAGE

  • Transfer to PVDF membrane

  • Block and incubate with RWDD3 antibody (typically 1:1000 dilution)

  • Detect using appropriate secondary antibody and chemiluminescence

  • This approach quantifies total RWDD3 protein levels and can detect changes following experimental manipulations

• Functional assays following RWDD3 knockdown/overexpression:

  • After modulating RWDD3 expression, use antibodies to confirm knockdown/overexpression efficiency

  • Combine with proliferation assays (MTT, BrdU)

  • Assess apoptosis (Annexin V/PI staining)

  • Evaluate cell migration and invasion (transwell assays)

  • These approaches have been successfully used to demonstrate that RWDD3 knockdown decreases proliferation, increases apoptosis, and reduces migration of glioblastoma cells

For all these methods, comparison between glioblastoma cell lines (U87, U251) and normal human astrocytes serves as an important control, as RWDD3 is significantly upregulated in glioblastoma cells .

How can RWDD3 antibodies be used to investigate the regulation of MMP2 and MMP9 in glioblastoma invasion?

Matrix metalloproteinases MMP2 and MMP9 play critical roles in glioblastoma invasion by cleaving type IV and V collagens and participating in the breakdown of the extracellular matrix . Research has shown that inhibition of RWDD3 expression leads to reduced glioblastoma cell migration and invasion, accompanied by decreased protein levels of MMP2 and MMP9 . To investigate this relationship using RWDD3 antibodies, researchers can employ several approaches:

• Co-immunoprecipitation studies:

  • Use RWDD3 antibodies to pull down protein complexes

  • Probe for interactions with transcription factors known to regulate MMP2/MMP9 expression

  • This can identify whether RWDD3 directly or indirectly regulates MMP expression through protein-protein interactions

• ChIP assays:

  • Use RWDD3 antibodies for chromatin immunoprecipitation

  • Perform qPCR with primers specific to MMP2/MMP9 promoter regions

  • This determines if RWDD3 directly binds to MMP promoters or enhancers

• Dual immunofluorescence:

  • Stain cells or tissue sections with antibodies against RWDD3 and MMP2/MMP9

  • Analyze co-localization patterns under different conditions

  • This visualizes spatial relationships between these proteins

• Western blot analysis following RWDD3 modulation:

  • Manipulate RWDD3 expression through siRNA knockdown or overexpression

  • Use antibodies to confirm RWDD3 modulation

  • Probe for changes in MMP2/MMP9 protein levels

  • Include PI3K/AKT pathway components and their phosphorylated forms

  • This helps establish the signaling cascade from RWDD3 to MMPs

• Gelatin zymography:

  • Following RWDD3 knockdown/overexpression, assess MMP activity

  • Correlate with RWDD3 protein levels determined by immunoblotting

  • This measures functional consequences of RWDD3-mediated MMP regulation

Research has demonstrated that activation of PI3K/AKT signaling (using the agonist 740Y-P) can prevent the suppressive effects of RWDD3 downregulation on MMP2/MMP9 expression and glioblastoma cell migration . This suggests that RWDD3 regulates MMPs at least partly through the PI3K/AKT pathway, which can be further explored using phospho-specific antibodies in the experimental approaches described above.

What are the common challenges in RWDD3 antibody specificity, and how can researchers validate antibody performance?

Researchers frequently encounter specificity challenges when working with RWDD3 antibodies. To address these issues and ensure reliable results, consider the following validation approaches:

• Multiple antibody verification:

  • Use at least two different antibodies targeting distinct epitopes of RWDD3

  • Compare staining patterns and molecular weight detection

  • Concordant results increase confidence in specificity

• Knockdown/knockout controls:

  • Perform siRNA knockdown or CRISPR/Cas9 knockout of RWDD3

  • Verify reduction/absence of signal with RWDD3 antibodies

  • This is the gold standard for antibody validation

• Overexpression controls:

  • Express tagged RWDD3 (e.g., FLAG or GFP-tagged)

  • Confirm detection with both tag-specific and RWDD3-specific antibodies

  • Verify co-localization in imaging applications

• Peptide competition assays:

  • Pre-incubate RWDD3 antibody with excess immunizing peptide

  • Specific signals should be blocked/reduced

  • Non-specific signals will remain

• Tissue panel validation:

  • Test antibodies on tissues with known RWDD3 expression patterns

  • Cerebellum, pituitary, heart, kidney, liver should show high expression

  • Thalamus and spinal cord should show lower expression

• Isoform considerations:

  • Determine which RWDD3 isoforms your antibody detects

  • Verify molecular weight correspondence with predicted isoform sizes

  • Note that isoform 1 and isoform 2 are expressed in glioma tumors

• Cross-reactivity assessment:

  • Test antibodies on samples from different species if cross-reactivity is claimed

  • Verify that the reactivity matches sequence homology predictions

  • Commercial RWDD3 antibodies often claim reactivity with human, mouse, and rat samples

Companies that supply RWDD3 antibodies, such as ProSci Inc., Abbiotec, and Boster Bio, typically perform affinity chromatography purification to improve specificity . Researchers should review the validation data provided by manufacturers and conduct their own validation experiments appropriate to their specific applications and samples.

How can researchers address contradictory findings when studying RWDD3's role in inflammatory signaling pathways?

RWDD3 has complex roles in inflammatory signaling, which can sometimes lead to apparently contradictory findings. To address and reconcile these contradictions, researchers should consider:

This multi-faceted approach can help reconcile seemingly contradictory findings by revealing that RWDD3 may simultaneously promote and inhibit different aspects of inflammatory signaling, depending on cellular context, timing, and specific pathway components.

What are the best approaches for quantifying RWDD3 protein levels in patient samples and correlating them with clinical outcomes?

These approaches, when implemented rigorously, can establish whether RWDD3 serves as an independent prognostic biomarker and potential therapeutic target, as suggested by current research showing correlation between high RWDD3 expression and shorter survival in glioblastoma patients .

What are the emerging applications of RWDD3 antibodies in studying sumoylation in cancer progression?

RWDD3's role as an enhancer of SUMO conjugation positions it as a critical player in cancer biology, with several emerging applications for RWDD3 antibodies:

• Therapeutic target validation:

  • Use RWDD3 antibodies to monitor protein levels following treatment with sumoylation inhibitors

  • Correlate RWDD3-mediated sumoylation changes with cancer cell sensitivity to therapy

  • This approach helps identify patients likely to respond to sumoylation-targeting treatments

• Biomarker development:

  • Develop immunoassays for detecting sumoylated proteins in patient samples

  • Use RWDD3 antibodies in multiplexed formats to create "sumoylation signatures"

  • Correlate these signatures with treatment response and disease progression

• Proximity-based proteomics:

  • Employ BioID or APEX2 fusion proteins with RWDD3

  • Use antibodies to identify and validate the complete "sumoylome" in cancer cells

  • This reveals novel targets for therapeutic intervention

• Live-cell imaging:

  • Develop cell-permeable RWDD3 antibody fragments or nanobodies

  • Track dynamic changes in RWDD3 localization during cancer progression

  • Monitor sumoylation events in real-time using FRET-based approaches

• Single-cell analysis:

  • Apply RWDD3 antibodies in single-cell proteomics workflows

  • Characterize tumor heterogeneity based on RWDD3 and sumoylation patterns

  • This provides insights into resistant cell populations

RWDD3's involvement in hypoxia response makes it particularly relevant for studying tumor microenvironments. Under hypoxic conditions, RWDD3 expression is induced and it negatively modulates HIF1A signaling by increasing HIF1A sumoylation . This affects transcriptional activity and expression of target genes like VEGFA during hypoxia , suggesting RWDD3 antibodies could be valuable tools for studying tumor vascularization mechanisms.

How can researchers design experiments to elucidate the relationship between RWDD3 expression and treatment resistance in glioblastoma?

Given RWDD3's role in glioblastoma progression through the PI3K/AKT pathway , investigating its relationship with treatment resistance requires carefully designed experiments:

• Patient-derived xenograft (PDX) models:

  • Establish PDX models from treatment-naïve and recurrent glioblastomas

  • Use RWDD3 antibodies to compare protein expression and localization

  • Correlate RWDD3 levels with response to standard therapies (temozolomide, radiation)

  • Test whether RWDD3 knockdown resensitizes resistant models

• In vitro resistance models:

  • Generate temozolomide-resistant glioblastoma cell lines

  • Use RWDD3 antibodies to monitor expression changes during resistance development

  • Perform RWDD3 knockdown or overexpression in resistant lines

  • Assess changes in chemosensitivity and radiation response

• Pathway analysis:

  • Use RWDD3 antibodies alongside phospho-specific antibodies for PI3K/AKT pathway components

  • Compare pathway activation in sensitive versus resistant cells

  • Test combination treatments targeting RWDD3 and PI3K/AKT signaling

  • This builds on findings that RWDD3 knockdown downregulates PI3K/AKT signaling

• Sumoylation target identification:

  • Immunoprecipitate with RWDD3 antibodies from sensitive and resistant cells

  • Identify differential sumoylation targets by mass spectrometry

  • Validate targets involved in DNA damage response or apoptosis pathways

  • This may reveal mechanisms by which RWDD3 confers treatment resistance

• 3D organoid models:

  • Develop patient-derived glioblastoma organoids

  • Use immunofluorescence with RWDD3 antibodies to assess spatial heterogeneity

  • Apply treatments and map resistance zones to RWDD3 expression patterns

  • This accounts for tumor microenvironment influences on resistance

• Longitudinal clinical samples:

  • Collect paired samples from glioblastoma patients before treatment and at recurrence

  • Use RWDD3 antibodies for immunohistochemistry or quantitative protein analysis

  • Correlate changes in RWDD3 expression with time to progression

  • This directly addresses whether RWDD3 upregulation occurs with treatment resistance

These approaches can establish whether RWDD3 serves as a biomarker of resistance and potential therapeutic target in recurrent glioblastoma, building on its established role in promoting cell survival and proliferation through PI3K/AKT signaling .

What novel techniques combining RWDD3 antibodies with other molecular tools could advance our understanding of glioblastoma pathogenesis?

Integrating RWDD3 antibodies with cutting-edge molecular technologies offers promising avenues for deeper insights into glioblastoma biology:

• Spatial transcriptomics with protein detection:

  • Combine RWDD3 antibody staining with spatial transcriptomic platforms

  • Map RWDD3 protein expression alongside transcriptional programs

  • This reveals spatial relationships between RWDD3 and downstream genes in intact tumor tissue

  • Particularly valuable for exploring RWDD3's relationship with MMP2/MMP9 expression

• CRISPR screens with RWDD3 pathway reporters:

  • Develop reporter systems for RWDD3-regulated pathways

  • Perform genome-wide CRISPR screens to identify modulators

  • Use RWDD3 antibodies to validate hits and assess pathway impact

  • This identifies synergistic targets for combination therapy

• Intravital imaging:

  • Create fluorescent reporter glioblastoma cells with RWDD3 modulation

  • Implant in animal models with transparent cranial windows

  • Use antibodies to validate findings in fixed tissue sections

  • This captures dynamic RWDD3-dependent processes in vivo

• Proteomics of the tumor microenvironment:

  • Perform laser capture microdissection of distinct tumor regions

  • Use RWDD3 antibodies for region-specific protein analysis

  • Correlate with microenvironmental features (hypoxia, immune infiltration)

  • This contextualizes RWDD3 function within the heterogeneous tumor landscape

• Single-cell multi-omics:

  • Combine single-cell protein detection (using RWDD3 antibodies) with transcriptomics

  • Profile sumoylation status at single-cell resolution

  • Identify cell populations where RWDD3 drives specific phenotypes

  • This addresses tumor heterogeneity at unprecedented resolution

• Drug discovery platforms:

  • Develop high-content screening assays using RWDD3 antibodies

  • Screen compound libraries for molecules that modulate RWDD3 levels or activity

  • Validate hits in functional assays of glioblastoma cell behavior

  • This pipeline could identify novel RWDD3-targeting therapeutics

• Blood-brain barrier modeling:

  • Create in vitro BBB models with endothelial cells and glioblastoma cells

  • Use RWDD3 antibodies to study its role in tumor cell invasion across the BBB

  • Test how RWDD3 modulation affects response to BBB-penetrant therapies

  • This addresses a critical challenge in glioblastoma treatment

These integrated approaches could significantly advance our understanding of how RWDD3 contributes to glioblastoma pathogenesis through its regulation of the PI3K/AKT pathway, modulation of sumoylation, and effects on MMP expression and invasion , potentially revealing new therapeutic strategies for this devastating cancer.